State Street Corp Silverback Therapeutics, Inc. Transaction History

State Street Corp

  • $2.21 Trillion
  • Q1 2024

A detailed history of State Street Corp transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 1,604,550 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,604,550
Previous 576,980 178.09%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
N/A
1,027,570 Added 178.09%
1,604,550 $0
Q4 2023

Feb 14, 2024
BUY
N/A
40,820 Added 7.61%
576,980 $0
Q3 2023

Nov 14, 2023
BUY
N/A
97,609 Added 22.26%
536,160 $0
Q2 2023

Aug 14, 2023
BUY
N/A
309,360 Added 239.46%
438,551 $0
Q1 2023

May 15, 2023
BUY
N/A
43,300 Added 50.41%
129,191 $0
Q4 2022

Feb 14, 2023
BUY
$0.0 - $6.07 $0 - $111,081
18,300 Added 27.07%
85,891 $0
Q2 2022

Aug 15, 2022
SELL
$2.9 - $4.44 $802,148 - $1.23 Million
-276,603 Reduced 80.36%
67,591 $287,000
Q1 2022

May 16, 2022
BUY
$3.51 - $6.74 $70,835 - $136,019
20,181 Added 6.23%
344,194 $1.21 Million
Q4 2021

Feb 14, 2022
BUY
$6.03 - $11.67 $114,232 - $221,076
18,944 Added 6.21%
324,013 $2.16 Million
Q3 2021

Nov 15, 2021
BUY
$9.98 - $35.22 $805,885 - $2.84 Million
80,750 Added 36.0%
305,069 $3.05 Million
Q2 2021

Aug 16, 2021
BUY
$24.71 - $44.28 $794,550 - $1.42 Million
32,155 Added 16.73%
224,319 $6.93 Million
Q1 2021

May 17, 2021
BUY
$37.62 - $60.41 $7.23 Million - $11.6 Million
192,164 New
192,164 $8.38 Million

Others Institutions Holding SBTX

# of Institutions
117
Shares Held
47.9M
Call Options Held
442K
Put Options Held
42K
View Full List

About Silverback Therapeutics, Inc.

SBTX Quotes by TradingView
  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email